Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

conjoint

- PMLiVE

HIV meeting hears progress towards vaccine and cure

Hope for global treatment

- PMLiVE

Countries hail ‘landmark’ drug pricing transparency resolution, despite watering down

US among those in favour of price transparency

- PMLiVE

Huntsworth bolsters market access capabilities with Creativ-Ceutical

Adds new capabilities and global presence

- PMLiVE

Europe responding to gene therapy challenge, but picture remains fragmented

Germany, Italy and England using outcomes-based deals

- PMLiVE

Vertex chief Jeffrey Leiden to weigh in on Orkambi inquiry

Will be joined by chief commercial officer Stuart Arbuckle

- PMLiVE

‘Inflexible’ NICE blocking access to rare disease drugs

Spinraza most high profile example of access problem

- PMLiVE

Industry concerned about ‘rushed’ Brexit withdrawal legislation

The Patents Amendment could weaken the UK’s IP framework, warns biopharma

- PMLiVE

Beneluxa: the future of European market access?

Andrew McConaghie talks to Beneluxa’s Marcel van Raaij and Biogen’s Erik Smet about their groundbreaking deal on Spinraza and what it means for European market access

- PMLiVE

Digital applications are transforming the market access landscape

Optimising product value through digital technology

- PMLiVE

Encouraging data for Roche flu drug ahead of FDA decision

Trial looks at benefts in high risk groups

The European Medicines Agency: PRIME’d for access?

Leela Barham examines the impact of the EMA's PRIME fast track system after two years

Patients’willingness to pay

Considerations when developing an appropriate pricing strategy in self-pay markets

Research Partnership

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links